The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, doubleblind, placebo-controlled trial. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.